INTRODUCTION
============

Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder that occurs through the occlusion of the upper airways^[@r1]^, resulting in greater arousal and reduction of oxygen saturations during the sleep period^[@r2]^.

It is a frequent pathology, the prevalence of which may vary between 10% and 50% depending on the population, considering age group or gender^[@r2]^. The largest epidemiologic study on sleep undertaken in Brazil showed that 32.80% of 1042 volunteers researched had obstructive sleep apnea syndrome^[@r3]^.

Currently, treatment through continuous positive airway pressure (CPAP) is suggested as one of the therapeutic options for OSA patients, with an indication considered of moderate quality of evidence^[@r4]^. Its efficiency is seen in the reduction of the apnea index, improvement in oxygen saturation, daytime sleepiness, and patient quality of life, in moderate to severe OSA^[@r5]^.

There is a risk of cardiovascular disease amongst OSA patients, and the factors for this are complex. It is believed that there is interaction between oxidative stress, endothelial alterations, coagulation-fibrinolysis balance, systemic inflammatory processes, and autonomic alterations caused by the moment of apnea and sleep change, alongside external factors^[@r6]^. This process, thus, may cause a rise in blood pressure, cardiac arrhythmia, arterial coronary disease, atrial fibrillation, cerebrovascular diseases, and cardiac insufficiency^[@r7]^.

The autonomic alterations related to the emergence of diseases are inherent to the alteration of sympathetic activity in individuals with OSA. These alterations are seen in many studies through heart rate variability (HRV). High sympathetic activity is observed in OSA patients, justified by the increase in low frequency (LF) and very low frequency (VLF) domains, and in sympathovagal balance (LF/HF)^[@r8]^. The sympathetic balance is correlated to the severity of the disease, which is determined by the apnea index^[@r9]^.

The aim of this study, therefore, was to observe the changes in HRV, at medium and long treatment period, of patients with OSA treated with CPAP.

METHODS
=======

This is an integrative literature review conducted following the 6 steps proposed by Mendes et al.^[@r10]^. The follow steps were aim formulation, the definition of data collection, included and excluded criteria, article data research and analysis, interpretation and finally, the manuscript writing.

The research was conducted in May of 2018. The databases used for research were PubMed, Scopus, SciELO and Pedro. The keywords used were "heart rate variability", "obstructive sleep apnea" and "cpap", applied according to each databases configurations, with the Boolean indicator "AND".

For the selection of the included articles, title reading was conducted followed by reading of the abstracts of the manuscripts found. At this stage, the randomized and non-randomized studies that integrate the review were selected. After this selection, the texts were read throughout to observe whether they were adequate to the review's theme. The selection was conducted by two researches independently, and the items included in the review were agreed upon by both at the end through a new analysis.

In this review were included original, published, randomized and non-randomized articles released in the English language before and up to May 2018, which specified the effects of CPAP therapy in autonomic dysfunction, through the HRV analysis of OSA patients after at least one month of therapy.

The exclusion criteria are composed of non-original articles, such as literature reviews, letters, summaries, case studies and pilot studies or manuscripts that do not address the researched theme. Also, articles without subject apnea degree specified, without a description of the results before CPAP therapy and after the follow-up.

After the selection, a second analytical reading was done, to obtain and register the articles data, patient's characteristics, main outcome and results that demonstrate the effects (positive and negative) of CPAP use in heart rate variability of OSA patients, through linear and non-linear methods. The aim of this phase was qualitatively synthesized.

RESULTS
=======

The article selection process in the databases is displayed in [Figure 1](#f1){ref-type="fig"}. During the primary manuscript search 113 articles were found. Through title reading, duplicates in the same or on multiple databases were eliminated, with 67 articles remaining. Twenty one articles were excluded for not being original: 4 conference papers, 12 reviews, 2 letters, 1 case study, 1 research protocol and 1 pilot study. 4 articles were excluded for not having been released in the English language.

Figure 1Flow diagram for selection process.

After that, abstracts from 42 articles were read, 16 of which were excluded for not using HRV to evaluate the autonomic nervous system or not being related to the theme. Of the remaining 26 articles, 18 were excluded for not accompanying the patients for over a month, not presenting the HRV values pre and post-therapy, analyzing distinct groups with OSA and treated with CPAP with no initial and final analysis of the group's patients, or for having only graphics as results. At the end, 8 articles were selected to make up the results of this integrative review.

Characteristics of the studies
------------------------------

[Table 1](#t1){ref-type="table"} shows the methodological characteristics of the selected studies. Most of the articles found are cohort studies. Two of the studies have a control group, and only one of them proposed randomized patients for the intervention or stratification groups. Patient follow-up varied between 1 and 18 months. All studies used polysomnography for sleep study or evaluation of apnea presence. The HRV analysis was done mostly by electrocardiography. The method of analysis employed by the articles were linear; 3 of the studies used frequency domain analysis, 1 used time domain analysis and 4 used parameters from both domains.

###### 

Methodological characteristics of the selected studies.

  Article                                  Study Type   with Control Group   Randomized   HRV Analysis Method   HRV Domains   HRV Parameters
  ---------------------------------------- ------------ -------------------- ------------ --------------------- ------------- ---------------------------------------------------------------
  Dal-Fabbro et al., 2014^[@r11]^          CT           No                   Yes          PSG                   FDA           LF, HF, total power, ISAV
  Tasali et al., 2011^[@r12]^              CS           No                   No           ECG                   FDA           HFnu, LFnu, LF/HF
  Shiina et al., 2010^[@r13]^              CS           No                   No           ECG                   FDA           LF, HF, LF/HF
  Ferland; Poirier; Sériès, 2009^[@r14]^   CT           No                   No           Holter                FDA/TDA       LF, HF, LF/HF, SDNN, SDANN, rMSSD, NN50, pNN50
  Limphanudom et al., 2007^[@r15]^         PS           No                   No           ECG                   FDA/TDA       LF nu, HF nu, LHR, SDNN
  Chrysostomakis et al., 2006^[@r16]^      CS           Yes                  No           Holter                TDA           NN, SDNN, SD, pNN50, rMSSD, SDANN,
  Roche et al., 1999^[@r17]^               CS           No                   No           Holter                FDA/TDA       RR, rMSSD, pNN50, SDNN, SDANN, VLF, LF, HF, LF/HF, HFnu, LFnu
  Seaborn et al., 2012^[@r18]^             CS           Yes                  No           Holter ECG            FDA/TDA       RR, LF, HF, LF/HF, SDNN, rMSSD, pNN50

CS= Cohort Study; CT= Clinical Trial; ECG= Electrocardiography; PSG= polysomnography; TDA= Time Domain Analysis; FDA= Frequency Domain Analysis; ISAV= index of sleep autonomic variation; PS= prospective study.

On [Table 2](#t2){ref-type="table"} the general characteristics of the selected samples may be observed. one hundred and eighty-six patients composed the CPAP treatment groups; the control and intervention groups were not accounted for. Most patients in the study were men (138), the higher mean age was 61.4±8.1 and the smaller was 31.2±1.2 years. The patients were classified by severity of their apnea as severe or moderate to severe - through the Apnea-Hypopnea Index, the minimum value was 24.3±5.5 and the maximal 60.9±31.7.

###### 

Characteristics of the sample of selected studies.

  Article                          Sample Size   Male   Female   Age Mean ± SD   Apnea Severity        AHI Mean±SD
  -------------------------------- ------------- ------ -------- --------------- --------------------- -------------
  Dal-Fabbro et al., 2014          29            24     5        47.0±8.9        Moderate and severe   42.3±4.5
  Tasali et al., 2011              19            0      19       31.2±  1.2      Moderate              24.3 ± 5.5
  Shiina et al., 2010              50            45     5        54± 10          Severe                53.6± 22.1
  Ferland; Poirier; Sériès, 2009   18            16     2        49± 9           Severe                44.0±33.1
  Limphanudom et al., 2007         10            10     0        45.2 + 5.1      Moderate and severe   60.9 ± 31.7
  Chrysostomakis et al., 2006)     26            18     8        49.2 ± 7.6 y    Severe                58 ± 24
  Roche et al., 1999               14            12     2        61,4±8,1                              50,6±13,7
  Seaborn et al., 2012             20            13     7        50.8±11.7       Severe                38.0 ± 11.0

AHI: Apnea-Hypopnea Index

Main autonomic alterations through CPAP therapy
-----------------------------------------------

The literature shows that CPAP therapy produces changes in the OSA patients' autonomic nervous system at short, medium and long treatment period. These alterations demonstrate changes in sympathetic and parasympathetic activity, during sleep and vigil. The main parameters changes, in the analysis of time domain and frequency domain, can be observed on [Table 3](#t3){ref-type="table"}.

###### 

Changes in HRV after CPAP treatment in OSA patients.

                                              Frequency Domains Analysis                                                    
  ------- ----------------------------------- ---------------------------- ----------------------------------------------- -----------
          Article/Measurement unit            Baseline                     After CPAP                                      Follow-up
  LF      Dal-Fabbro et al., 2014             4,814.4±365.7                4,499.5±391.1                                   1 month
          Tasali et al., 2011 (Hz)            2580 ± 580                   2470 ± 572                                      2 months
          Shiina et al., 2010 (ms^2^)         474±485                      522±598                                         3 months
          Limphanudom et al., 2007 (nu)       57.74 + 13.6                 65.69 ± 13.98                                   1 months
                                              57.74 + 13.7                 58.62 ± 17.55                                   3 months
                                                                           56.03 + 17.13                                   6 months
          Seaborn et al., 2012 (log ms^2^)    5.2±1.2                      5.3±0.9; 0.9                                    1 month
          Ferland et al., 2009 (Ln ms^2^)     6.48±0.99                    5.99±1.31                                       1 month
                                                                           6.52±0.79[\*](#TFN3){ref-type="table-fn"}       1 year
          Roche et al., 1999 (ms^2^ Hz^-1^)   7,12 ± 1,06                  6,22 ± 1,18[\*\*](#TFN4){ref-type="table-fn"}   3 months
  HF      Dal-Fabbro et al., 2014             1,556.3±167.4                1,098.8±104.3[\*](#TFN3){ref-type="table-fn"}   1 month
          Tasali et al., 2011 (Hz)            1034 ± 359                   1629 ± 385                                      2 months
          Shiina et al., 2010 (ms^2^)         210±280                       256±372                                        3 months
          Limphanudom et al., 2007 (nu)       37.14 + 11.65                30.92 ± 14.05                                   1 month
                                                                           36.20 ± 16.75                                   3 months
                                                                           33.44  ±12.48                                   6 months
          Seaborn et al., 2012 (log ms^2^)    4.6±1.0                      4.8±0.7; 0.7                                    1 month
          Ferland et al., 2009 (Ln ms^2^)     5.45±0.98                    4.90±1.11                                       1 month
                                                                           5.46±0.84                                       1 year
          Roche et al., 1999 (ms^2^ Hz^-1^)   5,91 ± 0,87                  5,62 ± 0,91                                     3 months
  LF/HF   Tasali et al., 2011 (Hz)            4.1 ± 0.8                    2.3 ± 0.4 [\*](#TFN3){ref-type="table-fn"}       
          Shiina et al., 2010 (ms^2^)         210±280                      256±372[\*](#TFN3){ref-type="table-fn"}         3 months
          Limphanudom et al., 2007            1.86 ± 1.51                  2.61 ± 1.44                                     1 month
                                                                           2.23 ± 1.68                                     3 months
                                                                           1.96 ± 1.01                                     6 months
          Seaborn et al., 2012 (log ms^2^)    2.5±2.1                      1.9±1.1; 0.7                                    1 month
          Ferland et al., 2009 (Ln ms^2^)     3.32±2.45                    3.27±1.57                                       1 month
                                                                           3.31±1.77                                       1 year
          Roche et al., 1999 (ms^2^ Hz^-1^)   1,21±0,12                    1,11±0,15[\*\*](#TFN4){ref-type="table-fn"}     3 months
                                              Time Domain Analysis                                                          
          Article                             Baseline                     After CPAP                                      Follow-up
  SDNN    Limphanudom et al., 2007 (ms)       42.23 ± 14.60                43.55 ± 14.77                                   1 month
                                                                           47.31 + 18.15                                   3 months
                                                                           44.06 + 18.09                                   6 months
          Seaborn et al., 2012                35.1±17.0                    32.1±11.6; 0.7                                  1 month
          Ferland et al., 2009 (ms)           110±31                       107±44                                          1 month
                                                                           102±29                                          1 years
          Chrysostomakis et al., 2006 (ms)    67.5 ±27.3                   64.9±  24.8                                     2 months
          Roche et al., 1999 (ms)             123,6  ± 34,2                135,7 ± 47,6                                    3 months
  PNN50   Ferland et al., 2009 (ms)           18±13                        17±18                                           1 month
                                                                           18±14                                           1 year
          Chrysostomakis et al., 2006 (ms)    19.5±12.5                    16.1 ± 10.7                                     2 months
          Roche et al., 1999 (ms)             14,7 ± 10, 9                 14,4 ± 10, 6                                    3 months

Statistically significant change when comparing follow-up and baseline *p*\<0,05

Statistically significant change when comparing follow-up and baseline *p*\<0,001.

In the frequency domain analysis, some parameters did not behave the same way after treatment. Low Frequency was lower in 1,2 months^[@r11],[@r12]^ and 6 months^[@r13]^. Contradictorily, after 3 months^[@r13],[@r14]^ and 1 year it was elevated^[@r15]^. The same happened to HF, which was lower after 1 and 3 months^[@r11],[@r13],[@r16]^, but showed itself to be higher after 1 and 2 months, and 1 year^[@r12],[@r15],[@r17]^. The sympathovagal balance after CPAP tends to reduce after therapy^[@r12],[@r14],[@r16]^, although the change is not statistically significant in one study^[@r17]^.

In the Time domain analysis, the SDNN^[@r13],[@r16]^, pNN50^[@r15],[@r18]^, and parameters showed an increase after treatment. Square root of mean squared difference of successive normal-to-normal R-R intervals (rMSSD) showed a change too^[@r15],[@r18]^.

DISCUSSION
==========

The main finding in this review was that CPAP therapy induces change in OSA patients' parasympathetic tone, through changes in the HF, SDNN and pNN50. Patients with OSA tend to have a higher vagal tone, as expressed in HRV when compared to the control group^[@r18]^. In these patients, the influence of the vagal tone can be observed through the high frequency domains and components of pNN50 and rMSSD in HRV analysis. There is an indication that CPAP therapy produces significant change in these domains.

At the same time, it is not possible to observe alterations in time domain parameters during the day, although the pNN50 and rMSSD parameters are significantly reduced at night after therapy.

The decrease in sympathovagal balance through the LF/HF ratio during the sleep seems to be related to the decrease in HF. The LF/HF ratio reduced during the day and, as opposed to nighttime, was associated with an increase of HF^[@r16]^. The studies show that even when facing other comorbidities, such as polycystic ovarian syndrome^[@r12]^ or arterial rigidity^[@r14]^, CPAP produces change in HRV, as in other findings related to these diseases.

Conversely, in comparison to other therapies, whereas the weight loss provoked by 1 year of sibutramine^[@r15]^, in 24h analysis, rMSNN and pNN50 increased more during CPAP. During the day, the vagal component (HF) was higher for the CPAP group, as SDNN and SDANN when compared to the first month of therapy. The sibutramine group had no alteration in the LF, HF power and LF/HF ratio components.

Another finding in this review was the decrease in sympathetic activity through LF. It has been observed that in apnea episodes, oxygen decrease results in greater sympathetic nervous system activity at nighttime. These alterations persist at daytime, accompanied by higher nervous tone and higher concentration of sympathetic neuromodulators^[@r19]^.

The method of HRV analysis could provide different results. As observed in [Table 1](#t1){ref-type="table"}, some analyzed their patients for 24 hours and others for shorter time periods during sleep or daytime with different breathing methods. Considering that apnea episodes happen at nighttime, during sleep, the autonomic alterations can also be more significant during this period. As observed, abnormal breathing culminates in sympathetic activity peaks higher than the vagal ones^[@r20]^.

The review showed that the repercussion on HRV of CPAP treatment for OSA patients has moderate evidence. It demonstrated improvement in Apnea-Hypopnea Index and it also restore patients autonomic function in medium and long treatment time. Although theses benefits, could not be extend to men and women or patients in different age range due the studies characteristic.

The main limitation of this review was that there were few robust studies. It's important to acquire better scientific evidence of CPAP's effect in HRV. In this study, only 1 article was randomized^[@r11]^ and 2 with control groups^[@r17],[@r18]^. Furthermore, the different parameters and measurement units adopted by the authors made difficult result comparison.

The studies presented HRV analysis of different period of day and were used different methods of analysis. Also, a third confounding characteristic was de range of apnea hypopnea index. These points could compromise the quality of data and show bias.

CONCLUSION
==========

CPAP therapy influenced changes in heart rate variability of patients with obstructive sleep apnea. These changes are more significant when analyzing the frequency domain spectrum when compared to the time domain. Changes are also prominent at medium and long treatment period, with meaningful alterations in sympathovagal balance decrease and vagal component (HF) increase.
